Communiqués Protara Therapeutics, Inc.

Actions

TARA

US74365U1079

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 30/09/2026			Varia. 5j.	Varia. 1 janv.
3,050 ^USD	-4,98%		-13,84%	-42,78%

11/08	Protara Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
30/06	Protara Therapeutics : démission du directeur médical Leonardo Viana Nicacio	MT

Communiqués

08/09	Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference	AQ
11/08	Protara Therapeutics: Q2 Earnings Snapshot	AQ
11/08	Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update	AQ
20/05	Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA	AQ
18/05	Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026	AQ
15/05	Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC	AQ
13/05	Protara Therapeutics: Q1 Earnings Snapshot	AQ
13/05	Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update	AQ
27/04	Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting	AQ
10/03	Protara Therapeutics: Q4 Earnings Snapshot	AQ
10/03	Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update	AQ
23/02	TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer	AQ
19/02	Protara Therapeutics to Participate in Upcoming Investor Conferences	AQ
03/02	Protara Therapeutics, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	AQ
02/02	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
22/01	Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium	AQ
12/01	Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones	AQ
07/01	Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference	AQ
07/01	Protara Therapeutics Announces Dosing of First Patient in Phase 3 Registrational THRIVE-3 Trial of IV Choline Chloride in Patients on Long-Term Parenteral Support	AQ
05/01	Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations	AQ
08/12	Protara Announces Closing of $75 Million Public Offering	AQ
05/12	Protara Announces Pricing of $75 Million Public Offering	AQ
04/12	Protara Announces Proposed Public Offering	AQ
04/12	Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naive NMIBC Patients	AQ
03/12	Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients	AQ